Kelsey Goodwin
Stock Analyst at Piper Sandler
(4.91)
# 230
Out of 4,988 analysts
93
Total ratings
66.3%
Success rate
55.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LONA LeonaBio | Reiterated: Buy | $20 | $6.79 | +194.55% | 3 | Aug 27, 2026 | |
| OLMA Olema Pharmaceuticals | Reiterated: Buy | $40 | $9.82 | +307.33% | 5 | Aug 20, 2026 | |
| ERAS Erasca | Reiterated: Buy | $18 → $22 | $14.77 | +48.95% | 6 | Aug 12, 2026 | |
| CGON CG Oncology | Reiterated: Buy | $82 → $85 | $74.62 | +13.91% | 9 | Aug 7, 2026 | |
| JANX Janux Therapeutics | Reiterated: Buy | $26 | $16.59 | +56.72% | 8 | Aug 7, 2026 | |
| RLMD Relmada Therapeutics | Reiterated: Buy | $12 | $4.12 | +191.26% | 3 | Aug 7, 2026 | |
| BDTX Black Diamond Therapeutics | Reiterated: Buy | $8 | $1.96 | +308.16% | 5 | Aug 6, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $172 → $210 | $190.95 | +9.98% | 9 | Aug 6, 2026 | |
| OBX Obsidian Therapeutics | Initiated Coverage: Buy | $42 | $17.75 | +136.62% | 1 | Aug 4, 2026 | |
| ORIC ORIC Pharmaceuticals | Rated: Buy | $22 | $12.79 | +72.01% | 7 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $16 | $17.85 | -10.36% | 5 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $3.55 | +576.06% | 7 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 → $24 | $21.75 | +10.34% | 4 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $43.25 | -7.51% | 8 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.91 | - | 1 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $22.64 | +59.01% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $1.86 | n/a | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $2.53 | n/a | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $10.25 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.14 | n/a | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $17.61 | n/a | 1 | Oct 31, 2022 |
LeonaBio
Aug 27, 2026
Reiterated: Buy
Price Target: $20
Current: $6.79
Upside: +194.55%
Olema Pharmaceuticals
Aug 20, 2026
Reiterated: Buy
Price Target: $40
Current: $9.82
Upside: +307.33%
Erasca
Aug 12, 2026
Reiterated: Buy
Price Target: $18 → $22
Current: $14.77
Upside: +48.95%
CG Oncology
Aug 7, 2026
Reiterated: Buy
Price Target: $82 → $85
Current: $74.62
Upside: +13.91%
Janux Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $26
Current: $16.59
Upside: +56.72%
Relmada Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $12
Current: $4.12
Upside: +191.26%
Black Diamond Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $8
Current: $1.96
Upside: +308.16%
Revolution Medicines
Aug 6, 2026
Reiterated: Buy
Price Target: $172 → $210
Current: $190.95
Upside: +9.98%
Obsidian Therapeutics
Aug 4, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $17.75
Upside: +136.62%
ORIC Pharmaceuticals
Aug 4, 2026
Rated: Buy
Price Target: $22
Current: $12.79
Upside: +72.01%
Jul 24, 2026
Reiterated: Hold
Price Target: $16
Current: $17.85
Upside: -10.36%
May 20, 2026
Reiterated: Buy
Price Target: $24
Current: $3.55
Upside: +576.06%
May 15, 2026
Downgraded: Hold
Price Target: $14 → $24
Current: $21.75
Upside: +10.34%
Apr 20, 2026
Reiterated: Buy
Price Target: $40
Current: $43.25
Upside: -7.51%
Mar 26, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.91
Upside: -
Dec 8, 2025
Reiterated: Buy
Price Target: $36
Current: $22.64
Upside: +59.01%
May 15, 2025
Reiterated: Buy
Price Target: $5
Current: $1.86
Upside: n/a
May 7, 2025
Reiterated: Buy
Price Target: $8
Current: $2.53
Upside: n/a
Apr 1, 2025
Reiterated: Hold
Price Target: n/a
Current: $10.25
Upside: n/a
Jul 30, 2024
Downgraded: Hold
Price Target: n/a
Current: $4.14
Upside: n/a
Oct 31, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $17.61
Upside: n/a